BIOSTAR PHARM-B's UTD1 and UTD2 Clinical Data Selected for 2026 ASCO Annual Meeting

Stock News05-27

BIOSTAR PHARM-B (02563) announced that the latest clinical research data from four studies on its core products, UTD1 injection and UTD2 capsules, have been selected for poster presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The four selected studies focus on: a Phase I/II clinical trial of UTD2 for advanced breast cancer; a Phase II clinical trial of UTD2 for platinum-resistant ovarian cancer; a Phase II clinical trial of UTD1 for HER2-positive advanced breast cancer; and a Phase II clinical trial of UTD1 for castration-resistant prostate cancer. Leveraging the broad anti-cancer spectrum and high oral bioavailability of utidelone, BIOSTAR PHARM-B continues to advance its strategic development in new indication expansion and clinical development of oral formulations. The 2026 ASCO Annual Meeting is scheduled to take place from May 29 to June 2, 2026, at the McCormick Place Convention Center in Chicago, USA. The annual ASCO meeting brings together leading global clinical oncology experts to showcase the latest international advancements in clinical oncology research and cancer treatment technologies.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1134094097?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-27 22:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1134094097","market":"fut","top_or_hot":-1,"title":"BIOSTAR PHARM-B's UTD1 and UTD2 Clinical Data Selected for 2026 ASCO Annual Meeting","media":"Stock News","content":"<p>BIOSTAR PHARM-B (02563) announced that the latest clinical research data from four studies on its core products, UTD1 injection and UTD2 capsules, have been selected for poster presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The four selected studies focus on: a Phase I/II clinical trial of UTD2 for advanced breast cancer; a Phase II clinical trial of UTD2 for platinum-resistant ovarian cancer; a Phase II clinical trial of UTD1 for HER2-positive advanced breast cancer; and a Phase II clinical trial of UTD1 for castration-resistant prostate cancer. Leveraging the broad anti-cancer spectrum and high oral bioavailability of utidelone, BIOSTAR PHARM-B continues to advance its strategic development in new indication expansion and clinical development of oral formulations. The 2026 ASCO Annual Meeting is scheduled to take place from May 29 to June 2, 2026, at the McCormick Place Convention Center in Chicago, USA. The annual ASCO meeting brings together leading global clinical oncology experts to showcase the latest international advancements in clinical oncology research and cancer treatment technologies.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BIOSTAR PHARM-B's UTD1 and UTD2 Clinical Data Selected for 2026 ASCO Annual Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBIOSTAR PHARM-B's UTD1 and UTD2 Clinical Data Selected for 2026 ASCO Annual Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-27 22:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BIOSTAR PHARM-B (02563) announced that the latest clinical research data from four studies on its core products, UTD1 injection and UTD2 capsules, have been selected for poster presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The four selected studies focus on: a Phase I/II clinical trial of UTD2 for advanced breast cancer; a Phase II clinical trial of UTD2 for platinum-resistant ovarian cancer; a Phase II clinical trial of UTD1 for HER2-positive advanced breast cancer; and a Phase II clinical trial of UTD1 for castration-resistant prostate cancer. Leveraging the broad anti-cancer spectrum and high oral bioavailability of utidelone, BIOSTAR PHARM-B continues to advance its strategic development in new indication expansion and clinical development of oral formulations. The 2026 ASCO Annual Meeting is scheduled to take place from May 29 to June 2, 2026, at the McCormick Place Convention Center in Chicago, USA. The annual ASCO meeting brings together leading global clinical oncology experts to showcase the latest international advancements in clinical oncology research and cancer treatment technologies.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09939","symbol_name":"开拓药业-B","start_time":0,"source_url":"","article_id":"1134094097","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1134094097","pubTimestamp":1779892940,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"BIOSTAR PHARM-B (02563) announced that the latest clinical research data from four studies on its core products, UTD1 injection and UTD2 capsules, have been selected for poster presentation at the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","09939":"开拓药业-B","BK1515":"抗疫概念","BK1161":"生物科技","BK1574":"生物医药B类股","02563":"华昊中天医药-B"},"translate_title":"BIOSTAR PHARM-B的UTD1和UTD2临床数据入选2026年ASCO年会","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"09939":1,"02563":1},"content_text":"BIOSTAR PHARM-B (02563) announced that the latest clinical research data from four studies on its core products, UTD1 injection and UTD2 capsules, have been selected for poster presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The four selected studies focus on: a Phase I/II clinical trial of UTD2 for advanced breast cancer; a Phase II clinical trial of UTD2 for platinum-resistant ovarian cancer; a Phase II clinical trial of UTD1 for HER2-positive advanced breast cancer; and a Phase II clinical trial of UTD1 for castration-resistant prostate cancer. Leveraging the broad anti-cancer spectrum and high oral bioavailability of utidelone, BIOSTAR PHARM-B continues to advance its strategic development in new indication expansion and clinical development of oral formulations. The 2026 ASCO Annual Meeting is scheduled to take place from May 29 to June 2, 2026, at the McCormick Place Convention Center in Chicago, USA. The annual ASCO meeting brings together leading global clinical oncology experts to showcase the latest international advancements in clinical oncology research and cancer treatment technologies.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1134094097","isCrawlerRequest":true}